Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.

Humans Male Abiraterone Acetate / pharmacokinetics Prostatic Neoplasms, Castration-Resistant / drug therapy Aged Middle Aged Aged, 80 and over Follow-Up Studies Neoplasm Metastasis Antineoplastic Agents / pharmacokinetics
abiraterone acetate pharmacodynamics pharmacogenetics prostate cancer

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
31 May 2024
Historique:
received: 24 04 2024
revised: 23 05 2024
accepted: 27 05 2024
medline: 19 6 2024
pubmed: 19 6 2024
entrez: 19 6 2024
Statut: epublish

Résumé

This ABIGENE pharmacokinetic (PK) study sought mainly to characterize the unchanged drug PK during long-term abiraterone acetate (AA) administration in advanced prostate cancer patients (81 patients). It was observed that individual AA concentrations remained constant over treatment time, with no noticeable changes during repeated long-term drug administration for up to 120 days. There was no correlation between AA concentrations and survival outcomes. However, a significant association between higher AA concentrations and better clinical benefit was observed (

Identifiants

DOI: 10.3390/ijms25116058 PMID: 38892246
pubmed: 38892246
pii: ijms25116058
doi: 10.3390/ijms25116058
pii:
doi:

Substances chimiques

Abiraterone Acetate EM5OCB9YJ6
Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Emmanuel Chamorey (E)

Epidemiology and Biostatistics Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.
ORCID: 0000-0002-6841-4571

Marc Pujalte-Martin (M)

Medical Oncology Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.
ORCID: 0000-0002-4636-768X

Jean-Marc Ferrero (JM)

Medical Oncology Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.

Hakim Mahammedi (H)

Medical Oncology Department, Centre Jean Perrin, 63000 Clermond Ferrand, France.

Gwenaelle Gravis (G)

Medical Oncology Department, Institut Paoli Calmette, 13009 Marseille, France.

Guilhem Roubaud (G)

Department of Medical Oncology, Institut Bergonié, 33076 Bordeaux, France.

Philippe Beuzeboc (P)

Medical Oncology Department, Institut Curie, 75005 Paris, France.

Remy Largillier (R)

Medical Oncology Department, Centre Azuréen de Cancérologie, 06250 Mougins, France.

Delphine Borchiellini (D)

Medical Oncology Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.
Clinical Research Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.

Claude Linassier (C)

Medical Oncology Department, Centre Hospitalier Régional Universitaire, 37000 Tours, France.

Hélène Bouges (H)

Oncopharmacology Unit, Centre Antoine Lacassagne, University Côte d'Azur, 06189 Nice, France.

Marie-Christine Etienne-Grimaldi (MC)

Oncopharmacology Unit, Centre Antoine Lacassagne, University Côte d'Azur, 06189 Nice, France.
ORCID: 0000-0002-0758-311X

Renaud Schiappa (R)

Epidemiology and Biostatistics Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.
ORCID: 0000-0001-5104-9507

Jocelyn Gal (J)

Epidemiology and Biostatistics Department, Centre Antoine Lacassagne, University Côte d'Azur, 06000 Nice, France.
ORCID: 0000-0002-1802-118X

Gérard Milano (G)

Oncopharmacology Unit, Centre Antoine Lacassagne, University Côte d'Azur, 06189 Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Long-Term Pharmacokinetic Follow-Up of...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Androstanes › Androstènes › Acétate d'abiratérone › Long-Term Pharmacokinetic Follow-Up of...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › Long-Term Pharmacokinetic Follow-Up of...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Long-Term Pharmacokinetic Follow-Up of...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Long-Term Pharmacokinetic Follow-Up of...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Long-Term Pharmacokinetic Follow-Up of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Long-Term Pharmacokinetic Follow-Up of...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › Long-Term Pharmacokinetic Follow-Up of...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Long-Term Pharmacokinetic Follow-Up of...